Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor

May 24, 2024 06:33 PM AEST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

SHANGHAI, May 24, 2024 /PRNewswire/ -- Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been dosed in the Phase 1/2 trial of TSN1611 for the treatment of KRAS G12D mutant solid tumors in the United States. The program has been cleared for IND by U.S. FDA and China NMPA in Feb and April 2024, respectively.

TSN1611 is a highly selective and orally bioavailable small molecule targeting the G12D mutant of KRAS oncogene, with excellent enzymatic and cellular activities. It effectively engages both the ON-state (GTP-bound) and OFF-state (GDP-bound) of KRAS G12D. TSN1611 has demonstrated superior in vivo anti-tumor activity with a durable response across multiple animal models. TSN1611 features favorable physicochemical properties, oral pharmacokinetic profiles, and notable brain penetration potential to address a large unmet medical need.  

The ongoing first-in-human, multi-center clinical trial (NCT06385925) is designed to assess the safety, tolerability, pharmacokinetic profile, and preliminary anti-tumor activity in patients with advanced solid tumors harboring the KRAS G12D mutation. Patient recruitment is currently underway in the United States, with plans to initiate in China in the coming months.

"Preclinical profile indicated the potential of TSN1611 as a best-in-class molecule for treating cancers driven by KRAS G12D," said Dr. Tony Zhang, PhD., CEO of Tyligand Bioscience, "We are proud of our teams for the creativity, quality and speed in the discovery and early development efforts, and grateful for the support from our partners and investors in advancing TSN1611 one step closer toward the patients in need."

About Tyligand Bioscience: 

Founded in 2018, Tyligand Bioscience is a clinical stage biotech focusing on the discovery and development of transformative therapies for cancer. In addition to the KRAS G12D program, the company has several molecules in development, including TSN084, a Type II multi-kinase inhibitor; TSN222, a first in kind dual acting tumor immune agonist (DATIA®), and a platform for antibody drug conjugates (ADCs) featuring proprietary linkers and novel payloads. For more information about Tyligand Bioscience, please visit www.tyligand.com

KRAS mutations are the most common driver oncogenes, implicated in approximately 25% of all human cancers, with KRAS G12D emerging as a predominant isoform, which is particularly prevalent in pancreatic, colorectal, and non-small cell lung cancers. There exists an urgent need for effective therapies targeting KRAS G12D to improve patient outcomes.

CONTACT: Tyligand Bioscience, [email protected], https://www.tyligand.com


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.